The aim of the present randomized study was to compare the response rates and safety profile of nab-paclitaxel with sb-paclitaxel in Chinese patients with MBC.
Methods:
In the present open-label, multicenter study, 210 patients with MBC PD-1/PD-L1 assay were randomly assigned to receive nab-paclitaxel 260 mg/m<SU2</SU
intravenously (i.v.) over 30 min every 3 weeks (q3w) with no premedication or sb-paclitaxel 175 mg/m<SU2</SU i.v. over 3 h q3w with standard premedication.
Results:
The overall response rate was 54 and 29% in patients treated with nab-paclitaxel and sb-paclitaxel, respectively (P < 0.001). nab-paclitaxel induced a higher response rate in patients who were < 65 years old, patients who were receiving first-line therapy, patients who had no prior anthracycline therapy,
patients who had < or > 3 metastatic lesions, and patients who had visceral disease. The progression-free survival (PFS) period was 7.6 months for nab-paclitaxel and 6.2 months for sb-paclitaxel (P = 0.118). Despite the 49% higher paclitaxel dose in patients receiving nab-paclitaxel compared with patients receiving sb-paclitaxel, the safety profile was similar in both treatment groups. The most common grades 3 and 4 adverse event (AE) in both arms was neutropenia. The most common grade 3 nonhematologic AE was peripheral neuropathy, and no mTOR inhibitor grade 4 peripheral neuropathy was observed.
Conclusion:
Compared with sb-paclitaxel, nab-paclitaxel demonstrated superior efficacy, an acceptable safety profile, and BTSA1 price a trend toward increased PFS in patients with MBC.”
“A detailed analysis to extend the emission wavelength of InAs/InP nanostructures is presented employing InAs quantum dots (QDs), InAs quantum wells (QWs), and a combination of InAs QDs and QWs grown on InGaAsP/InP (100) by metal organic vapor phase epitaxy. First the optimized growth conditions of InAs QDs are established and an emission wavelength of 2 16 mu m is achieved by capping with strain reducing InGaAs layers Second, InAs QWs are grown under metal-stable conditions
with the longest emission wavelength of 2.26 mu m for a 4 nm QW Finally, a combined InAs QDs on QW structure is realized. The InAs QD density is drastically increased oil the QW and the longest emission wavelength of 2.46 mu m is obtained at 6 K from sparse huge QDs. These findings open routes to extend the emission wavelength in the InAs/InP materials system beyond 2.4 mu m using InAs QDs on QW structures. (C) 2009 American Institute of Physics. [doi: 10.1063/1.3257243]“
“Background-Copy number variants (CNVs) are a major form of genomic variation, which may be implicated in complex disease phenotypes. However, investigation of the role of CNVs in coronary heart disease (CHD) traits has been limited.